Valeriya V. Kozlova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valeriya V. Kozlova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Kirill Victorovich Lobastov
Pirogov Russian National Research Medical University
8 shared publications - Astanda Beslanovna Bargandzhiya
Pirogov Russian National Research Medical University
2 shared publications - Ilya Veniaminovich Schastlivtsev
Pirogov Russian National Research Medical University
2 shared publications A Fokin
South Ural State Medical University
1 shared publication- A. I. Nadvikov
Specialized Clinic of Innovative Phlebology “SKIF
1 shared publication - A. V. Gasnikov
Specialized Clinic of Innovative Phlebology “SKIF
1 shared publication
Latest Publications
- 5 October 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 10
Caprini Risk Score validity and prevention of venous thromboembolism in emergency surgery
Objective. To evaluate validity of the Caprini Risk Score (CRS) for predicting postoperative venous thromboembolism (VTE) in emergency surgery, as well as to investigate the impact of compliance with prophylactic protocols on the risk of postoperative thrombosis. Material and methods. A single-center prospective study included 267 patients after urgent or emergency major surgery. CRS scores were calculated before the intervention and at discharge. Routine mechanical and pharmacological prophylaxis for VTE was used after surgery. The primary endpoint was combination of asymptomatic and symptomatic deep vein thrombosis (DVT), identified with obligatory Doppler ultrasound before discharge, and pulmonary embolism (PE) verified by imaging or autopsy. Results. The incidence of postoperative VTE was 15.7% (95% CI, 11.8—20.6%), including two cases of PE (1 death). The number of VTE significantly correlated with final CRS score and increased from 2.3% in low-risk group to 55.6% in extremely high-risk group (V=0.509, p<0.001). CRS demonstrated high predictive ability: AUC=0.82 (95% CI, 0.76—0.89, p<0.001). The threshold was 5.5 scores with 81% sensitivity and 72% specificity. Compliance with the recommended anticoagulant dose was observed in 66% of patients. About 10% of patients received complete pharmacological and mechanical prophylaxis that did not affect the risk of postoperative VTE. In selective assessment, all patients with DVT had missed doses of heparins. Conclusion. The incidence of postoperative VTE in emergency surgery was 15.7% that correlated with CRS scores. Patients with CRS score ≥5 had a higher risk of complications.
- 5 October 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 10
Caprini Risk Score validity and prevention of venous thromboembolism in emergency surgery
Objective. To evaluate validity of the Caprini Risk Score (CRS) for predicting postoperative venous thromboembolism (VTE) in emergency surgery, as well as to investigate the impact of compliance with prophylactic protocols on the risk of postoperative thrombosis. Material and methods. A single-center prospective study included 267 patients after urgent or emergency major surgery. CRS scores were calculated before the intervention and at discharge. Routine mechanical and pharmacological prophylaxis for VTE was used after surgery. The primary endpoint was combination of asymptomatic and symptomatic deep vein thrombosis (DVT), identified with obligatory Doppler ultrasound before discharge, and pulmonary embolism (PE) verified by imaging or autopsy. Results. The incidence of postoperative VTE was 15.7% (95% CI, 11.8—20.6%), including two cases of PE (1 death). The number of VTE significantly correlated with final CRS score and increased from 2.3% in low-risk group to 55.6% in extremely high-risk group (V=0.509, p<0.001). CRS demonstrated high predictive ability: AUC=0.82 (95% CI, 0.76—0.89, p<0.001). The threshold was 5.5 scores with 81% sensitivity and 72% specificity. Compliance with the recommended anticoagulant dose was observed in 66% of patients. About 10% of patients received complete pharmacological and mechanical prophylaxis that did not affect the risk of postoperative VTE. In selective assessment, all patients with DVT had missed doses of heparins. Conclusion. The incidence of postoperative VTE in emergency surgery was 15.7% that correlated with CRS scores. Patients with CRS score ≥5 had a higher risk of complications.
- 18 September 2026
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
Comparative analysis of different modifications of the Caprini risk score in bariatric surgery
Background: Bariatric surgery is associated with an increased risk of postoperative venous thromboembolism (VTE). This study aimed to compare the predictive accuracy of the Caprini risk score (CRS 2005, 2010, and a population-specific version) for postoperative VTE in obese patients undergoing bariatric surgery. Methods: A prospective observational study was conducted from 2020 to 2025, involving 120 patients aged 26–75 years with obesity (BMI, 35-85 kg/m 2 ) undergoing laparoscopic bariatric surgery. VTE risk factors were assessed, including visceral fat area by computed tomography, estimated fat apron weight (FAW), severe obstructive sleep apnea (sOSA), CO 2 -pneumoperitoneum pressure, and popliteal vein blood flow measured intraoperatively via Doppler ultrasound scan. The primary outcome combined asymptomatic and symptomatic deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE) within 30 days postoperatively. Results: The incidence of postoperative VTE was 5.0% (95% CI, 2.3–10.5%), including one symptomatic PE (0.8%). Regression analysis identified CRS 2010, the estimated FAW, and sOSA as significant predictors of VTE. In the modified CRS, a FAW ≥11 kg was assigned 1 point, and the presence of sOSA was assigned 3 points. The improved predictive accuracy was observed with the CRS 2010, considering sOSA (AUC, 0.866; 95% CI, 0.794–0.939) and sOSA with FAW (AUC, 0.862; 95% CI, 0.784–0.939). The optimal cut-off value was ≥12 points (sensitivity 83%, specificity 81%). Conclusions: In bariatric surgery, CRS 2010 with sOSA and FAW showed a potential improvement in predicting postoperative VTE, with scores ≥12 indicating the highest risk. Although these findings remain preliminary and require further validation.
- 18 September 2026
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
Comparative analysis of different modifications of the Caprini risk score in bariatric surgery
Background: Bariatric surgery is associated with an increased risk of postoperative venous thromboembolism (VTE). This study aimed to compare the predictive accuracy of the Caprini risk score (CRS 2005, 2010, and a population-specific version) for postoperative VTE in obese patients undergoing bariatric surgery. Methods: A prospective observational study was conducted from 2020 to 2025, involving 120 patients aged 26–75 years with obesity (BMI, 35-85 kg/m 2 ) undergoing laparoscopic bariatric surgery. VTE risk factors were assessed, including visceral fat area by computed tomography, estimated fat apron weight (FAW), severe obstructive sleep apnea (sOSA), CO 2 -pneumoperitoneum pressure, and popliteal vein blood flow measured intraoperatively via Doppler ultrasound scan. The primary outcome combined asymptomatic and symptomatic deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE) within 30 days postoperatively. Results: The incidence of postoperative VTE was 5.0% (95% CI, 2.3–10.5%), including one symptomatic PE (0.8%). Regression analysis identified CRS 2010, the estimated FAW, and sOSA as significant predictors of VTE. In the modified CRS, a FAW ≥11 kg was assigned 1 point, and the presence of sOSA was assigned 3 points. The improved predictive accuracy was observed with the CRS 2010, considering sOSA (AUC, 0.866; 95% CI, 0.794–0.939) and sOSA with FAW (AUC, 0.862; 95% CI, 0.784–0.939). The optimal cut-off value was ≥12 points (sensitivity 83%, specificity 81%). Conclusions: In bariatric surgery, CRS 2010 with sOSA and FAW showed a potential improvement in predicting postoperative VTE, with scores ≥12 indicating the highest risk. Although these findings remain preliminary and require further validation.
- Open Access
- 15 December 2025
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Phlebitis after cyanoacrylate obliteration: Modern state of the problem
Phlebitis is a specific and widespread complication of cyanoacrylate obliteration (CAO). However, the definition, mechanisms of development, the incidence, and common treatment methods, have not been clarified. The study aimed to evaluate the incidence of phlebitis in a treated vein after CAO of varicose veins (VV) of the lower limbs and explore approaches for diagnosis and treatment of the latter complication. In March 2025, a systematic search for relevant papers was performed in PubMed, which included original studies with data about patients with VVs who underwent CAO and reported the incidence of post-procedure cyanoacrylate phlebitis (CAP). The primary endpoint was the presence of confirmed phlebitis and/or a phlebitis-like reaction in treated veins according to the original study criteria. Extracted data were summarized with a random effects model. A literature search identified 114 references, of which 24 full-text studies reporting 27,362 interventions were included in the analysis. Additionally, data from our study about the use of the original cyanoacrylate composition with “VACOV” technique in 53 patients were included. The incidence of CAP was 11% (95% CI: 7–14%; p < 0.001, I 2 = 92.4%). The subgroup analysis according to methods of glue embolization revealed significant differences in CAP incidence with VariClose (Turkey), VenaBlock (Turkey) and VenaSeal (USA): 4% (95% CI: 2–6%), 3% (95% CI: 0–5%), and 16% (95% CI: 11–21%), respectively (p < 0.001). Pain along the treated vein, palpatory tenderness, hyperemia, and swelling were the most common clinical manifestations of phlebitis. The treatment of CAP was heterogeneous and included as follows: nonsteroidal anti-inflammatory drugs, antihistamines, glucocorticoids, and antibiotics. CAP is a frequent specific complication of CAO with an incidence of 11% without defined diagnostic criteria and common treatment and prophylaxis approaches.
- 15 December 2025
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Open AccessPhlebitis after cyanoacrylate obliteration: Modern state of the problem
Phlebitis is a specific and widespread complication of cyanoacrylate obliteration (CAO). However, the definition, mechanisms of development, the incidence, and common treatment methods, have not been clarified. The study aimed to evaluate the incidence of phlebitis in a treated vein after CAO of varicose veins (VV) of the lower limbs and explore approaches for diagnosis and treatment of the latter complication. In March 2025, a systematic search for relevant papers was performed in PubMed, which included original studies with data about patients with VVs who underwent CAO and reported the incidence of post-procedure cyanoacrylate phlebitis (CAP). The primary endpoint was the presence of confirmed phlebitis and/or a phlebitis-like reaction in treated veins according to the original study criteria. Extracted data were summarized with a random effects model. A literature search identified 114 references, of which 24 full-text studies reporting 27,362 interventions were included in the analysis. Additionally, data from our study about the use of the original cyanoacrylate composition with “VACOV” technique in 53 patients were included. The incidence of CAP was 11% (95% CI: 7–14%; p < 0.001, I 2 = 92.4%). The subgroup analysis according to methods of glue embolization revealed significant differences in CAP incidence with VariClose (Turkey), VenaBlock (Turkey) and VenaSeal (USA): 4% (95% CI: 2–6%), 3% (95% CI: 0–5%), and 16% (95% CI: 11–21%), respectively (p < 0.001). Pain along the treated vein, palpatory tenderness, hyperemia, and swelling were the most common clinical manifestations of phlebitis. The treatment of CAP was heterogeneous and included as follows: nonsteroidal anti-inflammatory drugs, antihistamines, glucocorticoids, and antibiotics. CAP is a frequent specific complication of CAO with an incidence of 11% without defined diagnostic criteria and common treatment and prophylaxis approaches.
- 11 June 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 41 (2) , 163-168
Secondary thigh telangiectasias after endovenous laser ablation of the great saphenous vein
Objectives: To assess the incidence of secondary telangiectasias (TAEs) after endovenous laser ablation (EVLA) of the great saphenous vein (GSV) and discuss the possible risk factors for its development. Method: This prospective observational study enrolled 123 lower limbs of 103 patients with varicose veins of C2 or C4 clinical classes who underwent EVLA of the GSV trunk from the saphenofemoral junction to the below knee level without simultaneous removal of varicose tributaries and/or perforating veins. The primary outcome was the occurrence and amount of secondary TAEs (matting) that developed at the medial aspect of the thigh along the treated GSV within a 3-month follow-up. The assessment was made by analysis of before and after photos by three experienced surgeons using a four-point scale. Fleiss’ Kappa was used to measure the agreement between the assessors. Results: Secondary TAE development was reported in 26 limbs (21.1%; 95% CI, 15.0-29.0%). Almost perfect agreement was observed between assessors for any matting (κ = 0.92; p < .0001) and different amounts of it (κ = 0.93, κ = 0.90, κ = 0.85, and κ = 1.00 for the score of 0, 1, 2, and 3, respectively). The most prevalent was a low amount of new TAEs (score of 1 in 17.9%). The only significant difference between the patients with and without secondary TAEs was age: 52.5 (IQR, 43-61) versus 40 (IQR, 34-53) years old. Conclusions: In most cases (96,8%), secondary TAEs are either absent or could be found in a low amount. Older patients are more predisposed to its development.
- 11 June 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 41 (2) , 163-168
Secondary thigh telangiectasias after endovenous laser ablation of the great saphenous vein
Objectives: To assess the incidence of secondary telangiectasias (TAEs) after endovenous laser ablation (EVLA) of the great saphenous vein (GSV) and discuss the possible risk factors for its development. Method: This prospective observational study enrolled 123 lower limbs of 103 patients with varicose veins of C2 or C4 clinical classes who underwent EVLA of the GSV trunk from the saphenofemoral junction to the below knee level without simultaneous removal of varicose tributaries and/or perforating veins. The primary outcome was the occurrence and amount of secondary TAEs (matting) that developed at the medial aspect of the thigh along the treated GSV within a 3-month follow-up. The assessment was made by analysis of before and after photos by three experienced surgeons using a four-point scale. Fleiss’ Kappa was used to measure the agreement between the assessors. Results: Secondary TAE development was reported in 26 limbs (21.1%; 95% CI, 15.0-29.0%). Almost perfect agreement was observed between assessors for any matting (κ = 0.92; p < .0001) and different amounts of it (κ = 0.93, κ = 0.90, κ = 0.85, and κ = 1.00 for the score of 0, 1, 2, and 3, respectively). The most prevalent was a low amount of new TAEs (score of 1 in 17.9%). The only significant difference between the patients with and without secondary TAEs was age: 52.5 (IQR, 43-61) versus 40 (IQR, 34-53) years old. Conclusions: In most cases (96,8%), secondary TAEs are either absent or could be found in a low amount. Older patients are more predisposed to its development.
- 27 December 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (4)
Phlebolymphedema: Modern Views and Methods of Correction
Objective. To summarize the available data on the role of lymphatic insufficiency in CVI and its correction using CVD treatment approaches. Material and methods. We reviewed the PubMed and eLibrary databases using the keywords «phlebolymphedema», as well as analyzed available articles. Results. Revising the Starling’s law excluding fluid reabsorption at the venous end of the capillary and placing responsibility for fluid drainage on lymphatic system is important for the concept of phlebolymphedema. Progressive venous hypertension and increased plasma filtration can lead to functional insufficiency and damage to lymphatic system. Available data confirm progressive impairment of lymphatic outflow in parallel with progression of CVD. Modern methods of morphofunctional assessment of superficial lymphatic system, in particular ICG lymphography, allows us to take a new look at pathogenesis of CVI. Standard methods of CVD treatment can have a positive effect on lymphatic outflow, but available data are contradictory. Therapeutic effect of compression therapy is mainly limited to fluid movement through the interstitium towards intact lymphatic vessels. Various drugs including micronized purified flavonoid fraction demonstrate a positive effect on lymphatic drainage. Appropriate therapy is followed by effective relief of venospecific subjective symptoms, chronic edema and trophic disorders. Surgery for superficial and deep veins can improve lymphatic drainage, but clinical results are naturally worse in case of lymphatic insufficiency. Conclusion. Damage to lymphatic system is essential for progressive forms of CVD that emphasizes the need for further study of this issue and development of prevention methods.
- 27 December 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (4)
Phlebolymphedema: Modern Views and Methods of Correction
Objective. To summarize the available data on the role of lymphatic insufficiency in CVI and its correction using CVD treatment approaches. Material and methods. We reviewed the PubMed and eLibrary databases using the keywords «phlebolymphedema», as well as analyzed available articles. Results. Revising the Starling’s law excluding fluid reabsorption at the venous end of the capillary and placing responsibility for fluid drainage on lymphatic system is important for the concept of phlebolymphedema. Progressive venous hypertension and increased plasma filtration can lead to functional insufficiency and damage to lymphatic system. Available data confirm progressive impairment of lymphatic outflow in parallel with progression of CVD. Modern methods of morphofunctional assessment of superficial lymphatic system, in particular ICG lymphography, allows us to take a new look at pathogenesis of CVI. Standard methods of CVD treatment can have a positive effect on lymphatic outflow, but available data are contradictory. Therapeutic effect of compression therapy is mainly limited to fluid movement through the interstitium towards intact lymphatic vessels. Various drugs including micronized purified flavonoid fraction demonstrate a positive effect on lymphatic drainage. Appropriate therapy is followed by effective relief of venospecific subjective symptoms, chronic edema and trophic disorders. Surgery for superficial and deep veins can improve lymphatic drainage, but clinical results are naturally worse in case of lymphatic insufficiency. Conclusion. Damage to lymphatic system is essential for progressive forms of CVD that emphasizes the need for further study of this issue and development of prevention methods.
- Open Access
- 16 November 2024
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 21 (2) , 32-43
Efficacy and safety of direct oral anticoagulants in patients with implanted inferior vena cava filters: a systematic review and meta-analysis
Nowadays, vitamin K antagonists (VKA) remain the anticoagulants of choice for patients with implanted inferior vena cava (IVC) filters, while the use of direct oral anticoagulants (DOACs) is controversial. Aim of the review – the study aimed to compare the efficacy and safety of DOACs and VKAs in patients with IVC filters. A systematic search for the relevant papers was performed in Medline (Pubmed) and the Cochrane Library according to the PRISMA guidelines. The inclusion criteria for the analysis were as follows: comparative studies of any design that enrolled patients with verified venous thromboembolism (VTE) who underwent IVC filter implantation and received long-term therapy with DOACs or VKAs with reported numbers of thrombotic and hemorrhagic complications within a follow-up of ≥3 months. The primary endpoints were VTE recurrence and major bleeding. Secondary endpoints included deep vein thrombosis (DVT), IVC thrombosis or filter occlusion, pulmonary embolism (PE), clinically relevant non-major (CRNM) bleeding, any bleeding, and all-cause mortality. Meta-analysis was performed using a random or fixed-effect model depending on the identified heterogeneity. As a result of the literature search was performed in July 2024 and identified 189 references, of which four articles were selected for full-text analysis after screening and excluding 174 irrelevant papers. The final qualitative analysis and quantitative synthesis included two retrospective cohort studies of 302 patients comparing rivaroxaban and warfarin. There were no significant differences between rivaroxaban and warfarin according to the prespecified endpoints. Rivaroxaban is the only DOAC studied in patients with IVC filters. Anticoagulation with rivaroxaban is not less effective and safe than with warfarin after IVC filter implantation.
- 16 November 2024
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 21 (2) , 32-43
Open AccessEfficacy and safety of direct oral anticoagulants in patients with implanted inferior vena cava filters: a systematic review and meta-analysis
Nowadays, vitamin K antagonists (VKA) remain the anticoagulants of choice for patients with implanted inferior vena cava (IVC) filters, while the use of direct oral anticoagulants (DOACs) is controversial. Aim of the review – the study aimed to compare the efficacy and safety of DOACs and VKAs in patients with IVC filters. A systematic search for the relevant papers was performed in Medline (Pubmed) and the Cochrane Library according to the PRISMA guidelines. The inclusion criteria for the analysis were as follows: comparative studies of any design that enrolled patients with verified venous thromboembolism (VTE) who underwent IVC filter implantation and received long-term therapy with DOACs or VKAs with reported numbers of thrombotic and hemorrhagic complications within a follow-up of ≥3 months. The primary endpoints were VTE recurrence and major bleeding. Secondary endpoints included deep vein thrombosis (DVT), IVC thrombosis or filter occlusion, pulmonary embolism (PE), clinically relevant non-major (CRNM) bleeding, any bleeding, and all-cause mortality. Meta-analysis was performed using a random or fixed-effect model depending on the identified heterogeneity. As a result of the literature search was performed in July 2024 and identified 189 references, of which four articles were selected for full-text analysis after screening and excluding 174 irrelevant papers. The final qualitative analysis and quantitative synthesis included two retrospective cohort studies of 302 patients comparing rivaroxaban and warfarin. There were no significant differences between rivaroxaban and warfarin according to the prespecified endpoints. Rivaroxaban is the only DOAC studied in patients with IVC filters. Anticoagulation with rivaroxaban is not less effective and safe than with warfarin after IVC filter implantation.
- 13 September 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (3)
Place and role of compression therapy in modern minimally invasive treatment of varicose veins
Chronic venous disease (CVD), which includes varicose veins (VVs) of the lower limbs, is one of the most common and socially significant cardiovascular diseases. Despite the recognition of elastic compression as an essential method of CVD treatment, the benefits and feasibility of its usage during the perioperative period are being reconsidered. This narrative literature review aims to highlight the current evidence of the efficacy of elastic compression in relieving initial and residual vein-specific symptoms, reducing the risk of adverse events and VVs recurrence after surgical treatment. It also provides brief information about the mechanisms of action of compression therapy and discusses compliance issues. Nowadays, the concept of the influence of elastic compression on the diameter of veins and venous outflow velocity has been critically revised. It has been shown that deep veins are more sensitive to external compression, while it is impossible to reduce the caliber of superficial veins under the usual pressure. Extensive evidence indicates the efficacy of compression therapy in relieving venous symptoms, which may persist in 30—40% of patients after surgery. The usage of compression therapy perioperatively helps reduce the rate and severity of such adverse events as pain, bruising, and hyperpigmentation, as well as promotes the resorption of veins after sclerotherapy. However, the optimal mode and duration of compression have not been finally determined. Despite the presence of individual studies, the effect of compression therapy on the progression of CVD and the risk of VVs recurrence has not been proven. The main disadvantage of elastic compression is relatively low compliance, which varies between 26 and 74%. To improve it, both motivational conversations by the doctor and efforts by manufacturers to maintain maximal product quality while giving them optimal properties for comfortable wear are essential. Thus, compression therapy is still an important component of the perioperative treatment of VVs of the lower limb.
- 13 September 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (3)
Place and role of compression therapy in modern minimally invasive treatment of varicose veins
Chronic venous disease (CVD), which includes varicose veins (VVs) of the lower limbs, is one of the most common and socially significant cardiovascular diseases. Despite the recognition of elastic compression as an essential method of CVD treatment, the benefits and feasibility of its usage during the perioperative period are being reconsidered. This narrative literature review aims to highlight the current evidence of the efficacy of elastic compression in relieving initial and residual vein-specific symptoms, reducing the risk of adverse events and VVs recurrence after surgical treatment. It also provides brief information about the mechanisms of action of compression therapy and discusses compliance issues. Nowadays, the concept of the influence of elastic compression on the diameter of veins and venous outflow velocity has been critically revised. It has been shown that deep veins are more sensitive to external compression, while it is impossible to reduce the caliber of superficial veins under the usual pressure. Extensive evidence indicates the efficacy of compression therapy in relieving venous symptoms, which may persist in 30—40% of patients after surgery. The usage of compression therapy perioperatively helps reduce the rate and severity of such adverse events as pain, bruising, and hyperpigmentation, as well as promotes the resorption of veins after sclerotherapy. However, the optimal mode and duration of compression have not been finally determined. Despite the presence of individual studies, the effect of compression therapy on the progression of CVD and the risk of VVs recurrence has not been proven. The main disadvantage of elastic compression is relatively low compliance, which varies between 26 and 74%. To improve it, both motivational conversations by the doctor and efforts by manufacturers to maintain maximal product quality while giving them optimal properties for comfortable wear are essential. Thus, compression therapy is still an important component of the perioperative treatment of VVs of the lower limb.
- Open Access
- 17 May 2024
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 21 (1) , 55-62
Is it safe to discontinue anticoagulant after surgical treatment of varicose vein disease, which caused pulmonary embolism?
Superficial vein thrombosis, which is mostly caused by lower extremity varicose vein disease, can be complicated by pulmonary embolism. At the same time, the optimal duration of anticoagulant therapy for pulmonary embolism originated from varicose vein thrombosis is still under debate. On the one hand, the presence of varicose veins is considered a small risk factor for the development of venous thromboembolic events, which persistence determines an increased risk of relapse and requires prolonged anticoagulant therapy. On the other hand, elimination of varicose veins is associated with reduced risk of subsequent venous thromboembolic events. The article describes a clinical case of recurrent pulmonary embolism after surgical treatment of varicose vein disease, which caused primary pulmonary embolism. A 45-year-old patient suffering from left lower extremity varicose vein disease for 5 years was admitted to the intensive care unit with suspected pulmonary embolism. The further examination revealed signs of thrombotic occlusion of the segmental and subsegmental branches of the pulmonary arteries bilaterally and the middle lobe branch of the right pulmonary artery, as well as signs of the right-sided heart overload. In this case, pulmonary embolism was found to originate from thrombosis of the trunk of the great saphenous vein ofthe left lower extremity with a proximal border at the level of the lower leg. No signs of deep vein involvement were detected. The parenteral anticoagulant therapy initiated in the hospital was followed by switching to therapeutic doses of rivaroxaban. The signs of recanalization of involved veins were identified after 6 months of treatment, and it was decided to perform endovenous laser coagulation of the trunk of the great saphenous vein combined with mini-phlebectomy of varicose tributaries on continuous oral anticoagulant therapy. The rivaroxaban therapy was completed a month after intervention. However, 7 days later the patient was diagnosed with repeated symptomatic pulmonary embolism, which originated from thrombosis of the left popliteal vein. It was recommended to resume anticoagulant therapy of indefinite duration. The article discusses the issues of optimal duration of treatment for pulmonary embolism originated from thrombosis of superficial varicose veins, as well as the possible timing of completion of anticoagulant therapy after the intervention.
- 17 May 2024
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 21 (1) , 55-62
Open AccessIs it safe to discontinue anticoagulant after surgical treatment of varicose vein disease, which caused pulmonary embolism?
Superficial vein thrombosis, which is mostly caused by lower extremity varicose vein disease, can be complicated by pulmonary embolism. At the same time, the optimal duration of anticoagulant therapy for pulmonary embolism originated from varicose vein thrombosis is still under debate. On the one hand, the presence of varicose veins is considered a small risk factor for the development of venous thromboembolic events, which persistence determines an increased risk of relapse and requires prolonged anticoagulant therapy. On the other hand, elimination of varicose veins is associated with reduced risk of subsequent venous thromboembolic events. The article describes a clinical case of recurrent pulmonary embolism after surgical treatment of varicose vein disease, which caused primary pulmonary embolism. A 45-year-old patient suffering from left lower extremity varicose vein disease for 5 years was admitted to the intensive care unit with suspected pulmonary embolism. The further examination revealed signs of thrombotic occlusion of the segmental and subsegmental branches of the pulmonary arteries bilaterally and the middle lobe branch of the right pulmonary artery, as well as signs of the right-sided heart overload. In this case, pulmonary embolism was found to originate from thrombosis of the trunk of the great saphenous vein ofthe left lower extremity with a proximal border at the level of the lower leg. No signs of deep vein involvement were detected. The parenteral anticoagulant therapy initiated in the hospital was followed by switching to therapeutic doses of rivaroxaban. The signs of recanalization of involved veins were identified after 6 months of treatment, and it was decided to perform endovenous laser coagulation of the trunk of the great saphenous vein combined with mini-phlebectomy of varicose tributaries on continuous oral anticoagulant therapy. The rivaroxaban therapy was completed a month after intervention. However, 7 days later the patient was diagnosed with repeated symptomatic pulmonary embolism, which originated from thrombosis of the left popliteal vein. It was recommended to resume anticoagulant therapy of indefinite duration. The article discusses the issues of optimal duration of treatment for pulmonary embolism originated from thrombosis of superficial varicose veins, as well as the possible timing of completion of anticoagulant therapy after the intervention.